ANNX
Annexon IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$930.75M
P/E Ratio
—
EPS
$-1.34
Beta
1.15
52W High
$7.18
52W Low
$1.28
50-Day MA
$5.57
200-Day MA
$3.91
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-214.24M |
| Operating Margin | 0.00% |
| Return on Equity | -81.90% |
| Return on Assets | -43.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.42 |
| Price-to-Book | 4.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $160.47M |
| Float | $130.72M |
| % Insiders | 0.39% |
| % Institutions | 92.86% |
Analyst Ratings
Consensus ($13.71 target)
2
Strong Buy7
BuyData last updated: 4/7/2026